RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving bevacizumab together with combination chemotherapy may kill more
tumor cells.
PURPOSE: This phase III trial is studying how well giving induction therapy with bevacizumab
together with combination chemotherapy with or without capecitabine followed by bevacizumab
maintenance therapy in treating patients with metastatic colorectal cancer that cannot be
removed by surgery.
Jul 31,2008
All
18 Years
75 Years
18 Years
75 Years
672